PRESS RELEASE
News
-
-
REGULATED PRESS RELEASE
Biophytis annonce le règlement-livraison de son placement privé de 2,6 millions d'euros
Biophytis annonce le règlement-livraison de son placement privé de 2,6 millions d'euros. Les actions seront cotées sur Euronext Growth. Maxim Group LLC et Invest Securities ont agi en tant qu'agents de placement -
REGULATED PRESS RELEASE
Biophytis announces the settlement and delivery of its €2.6 million private placement
Biophytis announces the settlement and delivery of its €2.6 million private placement. New shares admitted for trading on Euronext Growth. Maxim Group LLC and Invest Securities involved in the transaction -
-
-
-
-
PRESS RELEASE
ALT5 Sigma Reports Strong Q4 and Full-Year 2024 Results, Achieves Milestones with Record Revenue, 1,000+ Customers, and Strategic Leadership Appointments
ALT5 Sigma Corp achieves record-breaking Q4 with $5.4 million revenue, surpasses 1,000 customer milestone, and appoints Ron Pitters as COO. Financial results and key developments highlighted -
PRESS RELEASE
Press Release: Qfitlia approved as the first therapy in the US to treat hemophilia A or B with or without inhibitors
Qfitlia (fitusiran) approved as the first US therapy for hemophilia A or B with or without inhibitors, offering consistent protection with few injections, using unique mechanism to reduce bleeding episodes -
PRESS RELEASE
Communiqué de presse : Qfitlia – premier médicament approuvé aux États-Unis pour le traitement des hémophilies A ou B, avec ou sans inhibiteurs
La FDA approuve Qfitlia, premier médicament pour hémophilies A/B. Protection contre saignements. Taux d'antithrombine abaissé. Mécanisme unique. Qfitlia réduit doses. Disponible en stylo ou flacon
